ASTX727

ASTX727 is a medication being studied for long-term treatment in patients who have previously shown benefits from using it in earlier clinical trials. This is an investigational drug that combines decitabine (a medication used to treat certain blood disorders) with cedazuridine (a substance that helps the body better absorb decitabine when taken by mouth). The medication is designed to be taken orally, making it more convenient for patients compared to traditional injectable treatments.

Acute Myeloid Leukemia (AML) – A blood and bone marrow cancer that occurs when abnormal white blood cells accumulate in the bone marrow. These abnormal cells interfere with the production of normal blood cells. The disease develops rapidly, affecting the production of healthy blood cells.

Myelodysplastic Syndrome (MDS) – A group of disorders where blood-forming cells in the bone marrow become abnormal and fail to produce enough healthy blood cells. The condition causes immature blood cells to fail to develop into healthy ones. The abnormal cells can build up in the bone marrow and blood.

Chronic Myelomonocytic Leukemia (CMML) – A condition that affects blood-forming cells in the bone marrow, causing an increase in white blood cells called monocytes. It shares features of both myelodysplastic syndrome and myeloproliferative disorders. The disease typically develops slowly over time.

Solid Tumors – Abnormal masses of tissue that usually do not contain cysts or liquid areas. They can occur in many parts of the body, including organs, muscles, and bones. Solid tumors form when cells divide and grow uncontrollably, forming a lump or mass.